User profiles for C. I. Fanello
 | Caterina A. FanelloKIMORU Unit Research Director, University of Oxford Verified email at ndm.ox.ac.uk Cited by 8966 |
WHO, the Global Fund, and medical malpractice in malaria treatment
…, KI Barnes, C Curtis, U d'Alessandro, CI Fanello… - The Lancet, 2004 - thelancet.com
However, WHO violates its own policy standard regularly. Most African countries reluctantly
cling to chloroquine, sulfadoxine-pyrimethamine, or the insignificantly better combination of …
cling to chloroquine, sulfadoxine-pyrimethamine, or the insignificantly better combination of …
[HTML][HTML] Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
…, PN Newton, MA Onyamboko, CI Fanello… - … England Journal of …, 2014 - Mass Medical Soc
Background Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia
and now poses a threat to the control and elimination of malaria. Mapping the geographic …
and now poses a threat to the control and elimination of malaria. Mapping the geographic …
[HTML][HTML] Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
AM Dondorp, CI Fanello, ICE Hendriksen, E Gomes… - The Lancet, 2010 - thelancet.com
… 8·1–36·9%) and corresponds to an overall number needed to treat to prevent one death
of 41 (95% CI 25–112). We recorded no heterogeneity between study sites (p=0·99). Eight …
of 41 (95% CI 25–112). We recorded no heterogeneity between study sites (p=0·99). Eight …
[HTML][HTML] Genetic architecture of artemisinin-resistant Plasmodium falciparum
…, Y Htut, KT Han, MP Kyaw, MA Faiz, CI Fanello… - Nature …, 2015 - nature.com
We report a large multicenter genome-wide association study of Plasmodium falciparum
resistance to artemisinin, the frontline antimalarial drug. Across 15 locations in Southeast Asia, …
resistance to artemisinin, the frontline antimalarial drug. Across 15 locations in Southeast Asia, …
Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial
…, K Bojang, JL Deen, J Evans, CI Fanello… - Clinical infectious …, 2012 - academic.oup.com
Background. Data from the largest randomized, controlled trial for the treatment of children
hospitalized with severe malaria were used to identify such predictors of a poor outcome from …
hospitalized with severe malaria were used to identify such predictors of a poor outcome from …
[HTML][HTML] Diagnosing Severe Falciparum Malaria in Parasitaemic African Children: A Prospective Evaluation of Plasma PfHRP2 Measurement
…, H Reyburn, S Joseph, K Chotivanich, CI Fanello… - 2012 - journals.plos.org
Background In African children, distinguishing severe falciparum malaria from other severe
febrile illnesses with coincidental Plasmodium falciparum parasitaemia is a major challenge. …
febrile illnesses with coincidental Plasmodium falciparum parasitaemia is a major challenge. …
Safety and efficacy of dihydroartemisinin/piperaquine (Artekin®) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children
C Karema, CI Fanello, C Van Overmeir… - Transactions of the …, 2006 - academic.oup.com
In Rwanda, amodiaquine + sulfadoxine/pyrimethamine (AQ + SP) is the current first-line
treatment for malaria, introduced in 2001 as an interim strategy before the future deployment of …
treatment for malaria, introduced in 2001 as an interim strategy before the future deployment of …
Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination
…, AA Sayeed, D Uddin, C Buckee, CI Fanello… - Elife, 2021 - elifesciences.org
Background: National Malaria Control Programmes (NMCPs) currently make limited use of
parasite genetic data. We have developed GenRe-Mekong, a platform for genetic …
parasite genetic data. We have developed GenRe-Mekong, a platform for genetic …
[HTML][HTML] High risk of severe anaemia after chlorproguanil-dapsone+ artesunate antimalarial treatment in patients with G6PD (A-) deficiency
CI Fanello, C Karema, P Avellino, G Bancone… - PloS one, 2008 - journals.plos.org
… In the first 4 days following CD+A treatment, mean haematocrit declined on average 1.94%
(95% CI 1.54 to 2.33) and 1.05% per day (95% CI 0.95 to 1.15) respectively in patients with …
(95% CI 1.54 to 2.33) and 1.05% per day (95% CI 0.95 to 1.15) respectively in patients with …
[PDF][PDF] Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa
OBJECTIVE: To explore the cost-effectiveness of parenteral artesunate for the treatment of
severe malaria in children and its potential impact on hospital budgets. METHODS: The costs …
severe malaria in children and its potential impact on hospital budgets. METHODS: The costs …